Endocrinology
- Born again: The many lives of metformin
Repurposing old drugs for new indications is not a new drug-development strategy.
- Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?
The authors appraise the evidence to date for weight loss with metformin in this patient population.
- How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?
Differentiating type 1 from type 2 amiodarone-induced thyrotoxicosis requires serologic testing, color Doppler ultrasonography, and radioisotope studies, and influences the choice of treatment.
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and managementA review of the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, factors related to toxicity risk, and principles of management.
- What is the rationale for the laboratory workup for suspected pheochromocytomas and paragangliomas?
The decision to test is best guided by clinical suspicion. Test results should be interpreted with careful consideration of how the samples were collected.
- To repeat or not to repeat? Measuring bone mineral density during anti-resorptive therapy or a drug holiday
The authors present evidence for and against monitoring bone mineral density in these patients, arguing against a one-size-fits-all approach.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
- Vitamin D: A metabolic bone disease perspective
When checking levels, clinicians should keep in mind that vitamin D levels fluctuate by season and time of day, and that different laboratories may use different assays that yield different results.
- Some complexities of diabetes and the heart
Patients with diabetes are at greater risk of coronary artery disease than their peers without diabetes. That’s straight and simple. But there the simplicity ends.